In a regulatory filing yesterday, Halozyme Therapeutics (HALO) disclosed that on September 6, the company was informed by its collaboration and license partner, F. Hoffmann-La Roche, Ltd. (RHHBY), that there will be a delay in the projected launch timing for Tecentriq SC, with ENHANZE in the U.S. “This delay is a result of the need to update Tecentriq SC CMC processes. These updates are expected to be completed in 2023 and are expected to support a potential launch of Tecentriq SC in the U.S. in 2024. There is no expected impact on ex-U.S. filings for Tecentriq SC,” Halozyme stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HALO:
- Halozyme announces approval of Roche Tecentriq SC using Enhanze technology
- Halozyme price target raised to $48 from $46 at Piper Sandler
- Halozyme price target lowered to $60 from $61 at H.C. Wainwright
- Halozyme raises FY23 non-GAAP EPS view to $2.65-$2.75 from $2.50-$2.65
- Halozyme reports Q2 non-GAAP EPS 74c, consensus 63c
